JP2022541435A5 - - Google Patents
Info
- Publication number
- JP2022541435A5 JP2022541435A5 JP2022502205A JP2022502205A JP2022541435A5 JP 2022541435 A5 JP2022541435 A5 JP 2022541435A5 JP 2022502205 A JP2022502205 A JP 2022502205A JP 2022502205 A JP2022502205 A JP 2022502205A JP 2022541435 A5 JP2022541435 A5 JP 2022541435A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193280A JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962875416P | 2019-07-17 | 2019-07-17 | |
| US62/875,416 | 2019-07-17 | ||
| PCT/US2020/042573 WO2021011885A1 (en) | 2019-07-17 | 2020-07-17 | Claudin18 antibodies and methods of treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193280A Division JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541435A JP2022541435A (ja) | 2022-09-26 |
| JP2022541435A5 true JP2022541435A5 (https=) | 2023-07-26 |
| JPWO2021011885A5 JPWO2021011885A5 (https=) | 2023-07-26 |
Family
ID=74211179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502205A Pending JP2022541435A (ja) | 2019-07-17 | 2020-07-17 | クローディン１８抗体及びがんを処置する方法 |
| JP2024193280A Pending JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193280A Pending JP2025032078A (ja) | 2019-07-17 | 2024-11-01 | クローディン１８抗体及びがんを処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US12345709B2 (https=) |
| EP (1) | EP3999548A4 (https=) |
| JP (2) | JP2022541435A (https=) |
| KR (2) | KR102777693B1 (https=) |
| CN (1) | CN114364701A (https=) |
| AU (2) | AU2020313978B2 (https=) |
| BR (1) | BR112022000371A2 (https=) |
| CA (1) | CA3146665A1 (https=) |
| IL (2) | IL289663B2 (https=) |
| MX (1) | MX2022000652A (https=) |
| WO (1) | WO2021011885A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3128502A1 (en) | 2019-02-01 | 2020-08-06 | Novarock Biotherapeutics, Ltd. | Anti-claudin 18 antibodies and methods of use thereof |
| JP2022541435A (ja) | 2019-07-17 | 2022-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン１８抗体及びがんを処置する方法 |
| KR20230079096A (ko) * | 2020-09-30 | 2023-06-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항체-약물 접합체를 포함하는 약제학적 조성물 및 약제학적 조성물의 용도 |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| CN117157105A (zh) | 2021-05-08 | 2023-12-01 | 荣昌生物制药(烟台)股份有限公司 | 一种抗Claudin18.2抗体及其抗体药物偶联物 |
| JP2024523166A (ja) * | 2021-06-15 | 2024-06-28 | ゼンコア インコーポレイテッド | クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体 |
| WO2022268200A1 (zh) * | 2021-06-25 | 2022-12-29 | 信达生物制药(苏州)有限公司 | 针对密蛋白18.2的抗体及其用途 |
| CR20240124A (es) * | 2021-08-09 | 2024-08-06 | Harbour Biomed Shanghai Co Ltd | Anticuerpo dirigido contra cldn18.2, anticuerpo biespecífico y el uso de estos |
| CN118139888A (zh) * | 2021-11-05 | 2024-06-04 | 正大天晴药业集团股份有限公司 | 抗cldn18.2抗体及其用途 |
| US20250249125A1 (en) * | 2022-04-08 | 2025-08-07 | Fred Hutchison Cancer Center | Anti-cd90 antibodies, binding fragments, and uses thereof |
| KR20250069817A (ko) * | 2022-06-03 | 2025-05-20 | 라노바 메디신즈 리미티드 | Pd-1 또는 pd-l1 억제제 및 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트를 사용한 암 치료 |
| TW202426059A (zh) * | 2022-11-30 | 2024-07-01 | 大陸商正大天晴藥業集團股份有限公司 | 抗cldn18.2抗體藥物偶聯物及其藥物組合物和用途 |
| KR20250120305A (ko) * | 2022-12-14 | 2025-08-08 | 아스텔라스 파마 유럽 비.브이. | Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법 |
| WO2024226646A2 (en) * | 2023-04-25 | 2024-10-31 | Memorial Sloan-Kettering Cancer Center | Dlk1 -targeting antibodies and uses thereof |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025206223A1 (ja) * | 2024-03-28 | 2025-10-02 | 早智子 月田 | 抗ヒトクローディン１８．２抗体及びその使用 |
| KR20250154059A (ko) | 2024-04-19 | 2025-10-28 | 강원대학교산학협력단 | Cldn18 단백질 또는 이를 코딩하는 유전자, 또는 프로모터 부위가 메틸화된 cldn18을 유효성분으로 포함하는 폐포 내 미세먼지 노출 진단용 바이오마커 조성물 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| AU2017294276B2 (en) * | 2016-07-08 | 2024-08-01 | Crage Medical Co., Limited | Antibody for anti-claudin 18A2 and use thereof |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| JP7398380B2 (ja) * | 2018-03-08 | 2023-12-14 | フェインズ セラピューティクス，インコーポレーテッド | 抗クローディン１８．２抗体及びその使用 |
| JOP20210022A1 (ar) | 2018-08-03 | 2021-01-28 | Amgen Inc | بنيات جسم مضاد لـ cldn18.2وcd3 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| JP2022541435A (ja) | 2019-07-17 | 2022-09-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | クローディン１８抗体及びがんを処置する方法 |
-
2020
- 2020-07-17 JP JP2022502205A patent/JP2022541435A/ja active Pending
- 2020-07-17 CN CN202080062500.1A patent/CN114364701A/zh active Pending
- 2020-07-17 KR KR1020227004165A patent/KR102777693B1/ko active Active
- 2020-07-17 MX MX2022000652A patent/MX2022000652A/es unknown
- 2020-07-17 IL IL289663A patent/IL289663B2/en unknown
- 2020-07-17 US US17/627,540 patent/US12345709B2/en active Active
- 2020-07-17 CA CA3146665A patent/CA3146665A1/en active Pending
- 2020-07-17 KR KR1020257007047A patent/KR20250044762A/ko active Pending
- 2020-07-17 IL IL313807A patent/IL313807A/en unknown
- 2020-07-17 BR BR112022000371A patent/BR112022000371A2/pt unknown
- 2020-07-17 WO PCT/US2020/042573 patent/WO2021011885A1/en not_active Ceased
- 2020-07-17 EP EP20839947.7A patent/EP3999548A4/en active Pending
- 2020-07-17 AU AU2020313978A patent/AU2020313978B2/en active Active
-
2022
- 2022-10-03 US US17/959,104 patent/US11834499B1/en active Active
-
2024
- 2024-11-01 JP JP2024193280A patent/JP2025032078A/ja active Pending
-
2025
- 2025-05-27 US US19/219,107 patent/US20260104418A1/en active Pending
- 2025-08-04 AU AU2025210899A patent/AU2025210899A1/en active Pending